Author:
Brandon Esther F. A.,Sparidans Rolf W.,Guijt Kees-Jan,Löwenthal Sjoerd,Meijerman Irma,Beijnen Jos H.,Schellens Jan H. M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference43 articles.
1. Jimeno JM: A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs 13 (suppl 1):S15–S19, 2002
2. Rinehart KL, Gravalos LG, Faircloth G, Jimeno J: Ecteinascidin (ET-743): Preclinical antitumor development of a marine derived natural product (abstract). Proc Am Assoc Cancer Res 36:2322, 1995
3. Jimeno JM, Faircloth G, Cameron L, Meely K, Vega E, Gómez A, Fernández Sousa-Faro JM, Rinehart K: Progress in the acquisition of new marine-derived anticancer compounds: development of Ecteinascidin-743 (ET-743). Drugs of the Future 21:1155–1165, 1996
4. D'Incalci M, Erba E, Damia G, Galliera E, Carassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT: Unique features of the mode of action of ET-743. The Oncologist 7:201–216, 2002
5. van Kesteren Ch, de Vooght MMM, López-Lázaro L, Mathôt RAA, Schellens JHM, Jimeno JM, Beijnen JH: Yondelis® (trabectedin, ET-743): The development of an anticancer agent of marine origen. Anticancer Drugs 14:487–502, 2003
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献